BPMC — Blueprint Medicines Share News
0.000.00%
Last trade - 00:00- $8.37bn
- $8.18bn
- $508.82m
U.S. RESEARCH ROUNDUP-American Water Works Company, Home Depot, Lowe's
U.S. RESEARCH ROUNDUP-Boeing, Moody's, S&P Global
Brief: Blueprint Medicines Ayvakyt(Avapritinib) Receives European Commission Approval For Indolent Systemic Mastocytosis
U.S. RESEARCH ROUNDUP-Adobe, Oracle, Visa
Brief: Blueprint Medicines' Harbor Part 1 Trial Data In Indolent Systemic Mastocytosis Showed Elenestinib Was Well-Tolerated
U.S. RESEARCH ROUNDUP- Airbnb, Brookdale Senior Living, Chevron
U.S. STOCKS ON THE MOVE-Exxon Mobil, Harley-Davidson, Sunnova Energy
Blueprint Medicines Corp reports results for the quarter ended in September - Earnings Summary
Blueprint Medicines Corp expected to post a loss of $2.37 a share - Earnings Preview
Brief: Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Blueprint Medicines Corp reports results for the quarter ended in June - Earnings Summary
Brief: Blueprint Medicines posts Q2 revenue USD 57.6 million
Blueprint Medicines Corp expected to post a loss of $2.54 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-ACM Research, Constellation Brands, SBA Communications
Genentech withdraws use of Gavreto in US for a type of thyroid cancer, says partner Blueprint (updated)
Brief: Blueprint Medicines - Genentech Announced Voluntary Withdrawal Of US Indication Of GAVRETO
Blueprint Medicines says partner Genentech withdraws use of Gavreto for thyroid cancer
Brief: Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline At 2023 Asco Annual Meeting
U.S. STOCKS ON THE MOVE-Galecto, Pinterest, Standard Lithium